Abstract:BACKGROUND:Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is one of the oldest known and most dangerous diseases. Although the spread of TB was controlled in the early 20th century using antibiotics and vaccines, TB has again become a threat because of increased drug resistance. There is still a lack of effective treatment regimens for a person who is already infected with multidrug-resistant Mtb (MDR-Mtb) or extensively drug-resistant Mtb (XDRMtb). In the past decades, many research groups have explored the drug resistance profiles of Mtb based on sequence data by GWAS, which identified some mutations that were significantly linked with drug resistance, and attempted to explain the resistance mechanisms. However, they mainly focused on several significant mutations in drug targets (e.g. rpoB, katG). Some genes which are potentially associated with drug resistance may be overlooked by the GWAS analysis.OBJECTIVE:In this article, our motivation is to detect potential drug resistance genes of Mtb using a heat diffusion model.METHODS:All sequencing data, which contained 127 samples of Mtb, i.e. 34 ethambutol-, 65 isoniazid-, 53 rifampicin- and 45 streptomycin-resistant strains. The raw sequence data were preprocessed using Trimmomatic software and aligned to the Mtb H37Rv reference genome using Bowtie2. From the resulting alignments, SAMtools and VarScan were used to filter sequences and call SNPs. The GWAS was performed by the PLINK package to obtain the significant SNPs, which were mapped to genes. The P-values of genes calculated by GWAS were transferred into a heat vector. The heat vector and the Mtb protein-protein interactions (PPI) derived from the STRING database were inputted into the heat diffusion model to obtain significant subnetworks by HotNet2. Finally, the most significant (P < 0.05) subnetworks associated with different phenotypes were obtained. To verify the change of binding energy between the drug and target before and after mutation, the method of molecular dynamics simulation was performed using the AMBER software.RESULTS:We identified significant subnetworks in rifampicin-resistant samples. Excitingly, we found rpoB and rpoC, which are drug targets of rifampicin. From the protein structure of rpoB, the mutation location was extremely close to the drug binding site, with a distance of only 3.97 Å. Molecular dynamics simulation revealed that the binding energy of rpoB and rifampicin decreased after D435V mutation. To a large extent, this mutation can influence the affinity of drug-target binding. In addition, topA and pyrG were reported to be linked with drug resistance, and might be new TB drug targets. Other genes that have not yet been reported are worth further study.CONCLUSION:Using a heat diffusion model in combination with GWAS results and protein-protein interactions, the significantly mutated subnetworks in rifampicin-resistant samples were found. The subnetwork not only contained the known targets of rifampicin (rpoB, rpoC), but also included topA and pyrG, which are potentially associated with drug resistance. Together, these results offer deeper insights into drug resistance of Mtb, and provides potential drug targets for finding new antituberculosis drugs.

Assessing the Progress of Mycobacterium Tuberculosis H37Rv Structural Genomics

The TB Structural Genomics Consortium: a decade of progress.

Three‐Dimensional Culture Modelling Reveals Divergent Mycobacterium tuberculosis Virulence and Antimicrobial Treatment Response

Protein Targets for Structure-Based Anti-Mycobacterium Tuberculosis Drug Discovery

Investigating Function Roles of Hypothetical Proteins Encoded by the Mycobacterium Tuberculosis H37Rv Genome

Target Prediction for an Open Access Set of Compounds Active Against Mycobacterium Tuberculosis

Protein targets for structure-based anti- Mycobacterium tuberculosis drug discovery

Mycobacterium Tuberculosis Biology Revealed by Proteome Profiling and Integration of Multi-Omics Data-Proteomics Insight into M-Tuberculosis Systems Biology

Mycobacterium tuberculosis functional network analysis by global subcellular protein profiling.

Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis

Application of Computational Methods in Understanding Mutations in Mycobacterium tuberculosis Drug Resistance

The Structural and Molecular Mechanisms of Mycobacterium tuberculosis Translational Elongation Factor Proteins

Single nucleotide variation catalog from clinical isolates mapped on tertiary and quaternary structures of ESX-1-related proteins reveals critical regions as putative Mtb therapeutic targets

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development

Tuberculosis: Current state of knowledge: An Epilogue

Structural Biology and Inhibition of the Mtb Cell Wall Glycoconjugates Biosynthesis on the Membrane

Recent Advances in Antitubercular Compounds Targeting Mycolic Acid Biosynthesis and Transport

Molecular and microbiological methods for the identification of nonreplicating Mycobacterium tuberculosis

A glimpse into the past and predictions for the future: the molecular evolution of the tuberculosis agent

Using a Heat Diffusion Model to Detect Potential Drug Resistance Genes of Mycobacterium Tuberculosis.